AGENT FOR PREVENTION AND/OR TREATMENT OF ALLERGIC INFLAMMATION IN CONJUNCTIVA
|Posted date||Jan 23, 2013|
|International application number||2012JP066207|
|International publication number||WO 2013005603|
|Date of international filing||Jun 26, 2012|
|Date of international publication||Jan 10, 2013|
|Title||AGENT FOR PREVENTION AND/OR TREATMENT OF ALLERGIC INFLAMMATION IN CONJUNCTIVA|
|Abstract||Provided are eye drops, and a subconjunctival injection drug for refractory allergic conjunctival disease, foremost for seasonal allergic conjunctivitis. This agent for prevention and/or treatment of allergic inflammation in the conjunctiva contains semaphorin-3A as an active component.|
|Outline of related art and contending technology||
In recent years, typified by hay fever has increased over the allergic diseases, involving multiple organs, occupies about 30% of the population, a great social problem. Pollen allergic conjunctival disease patient is estimated to be about 85% and property, there is a severe cases a proportion of at least 1% (non-patent document 1). As causing an increase in these allergic diseases, air pollutants and to be associated with pointed out.
Current, anti-allergic eye drops is formulated and type 9, anti-histamine eye drops is mostly used. However, non-steroidal ophthalmic drug effect is not enough. Allergic reaction type I allergic conjunctival disease is a collective term for disease involving the conjunctiva, a variety of lesion only anti-allergic eye drops cannot be suppressed, has been formulated steroid eye drops (non-patent document 2).
On the other hand, steroid eye drops is, of the effect is large, local eye increased intraocular pressure, cataract, retinopathy, the induction of infection progression, vascular abnormalities, skin conditions, there is a strong side effects such as hirsutism, cannot be easily continued. Therefore, as a therapeutic agent is administered to the non-steroidal instead, conjunctiva steroid drug more angular peripheral nerve paraesthesia, avoid side effects such as conjunctival vascular abnormalities, strong effect are eye drops has been developed.
The functions of the immune system revealed typical semaphorin molecule is Sema3A, the functions of the nervous system in the world as guidance factor has been industriously analysis (non-patent document 3) is, immune cell migration inhibitory effects have also been reported in recent years (non-patent document 4). T cell receptor (TCR) signaling pathway or inhibition of MAP kinase signaling pathway, or actin integrated inhibition than suppressing the activation of, in addition, complex pelexin-A4 NP-1/Sema3A as receptors for the negative T cell immune response was reported to be involved in the control (non-patent document 5 and 6).
However, allergic conjunctival disease semaphorin molecule Sema3A report to the effect that is not effective.
|Scope of claims||
(In Japanese)請求の範囲 [請求項1]
|IPC(International Patent Classification)||
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PE PG PH PL PT QA RO RS RU RW SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
Contact Information for " AGENT FOR PREVENTION AND/OR TREATMENT OF ALLERGIC INFLAMMATION IN CONJUNCTIVA "
- Public University Corporation Yokohama City University Research Promotion Division
- URL: http://www.yokohama-cu.ac.jp/
- Address: 22-2, Seto, Kanazawa-ku, Yokohama, Japan , 236-0027
- Phone: 81-45-787-2442
- Fax: 81-45-787-2025